Agenus | AGEN - Cash And Equivalent


Agenus reported $3.46M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Agenus USD 3.46M 6.08M Sep/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Celldex Therapeutics USD 28.87M 7.17M Dec/2025
CSL USD 2.16B 633M Jun/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Intrexon USD 9.34M 1.77M Jun/2024
J&J USD 19.71B 1.48B Dec/2025
Jiangsu Hengrui CNY 40.36B 4.24B Sep/2025
Karyopharm Therapeutics USD 37.67M 1.05M Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Merck EUR 2.25B 1.08B Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Northwest Biotherapeutics USD 4.56M 244K Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novavax USD 268.02M 14.28M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Veracyte USD 362.58M 47M Dec/2025